Frequently Asked Questions About XIENCE

Is XIENCE compatible with magnetic resonance imaging (MRI)?

Nonclinical testing has shown that the XIENCE Alpine stent, in single and in overlapped configurations up to 71 mm in length, can be safely scanned under the following conditions:*

  • Static magnetic field of 1.5 or 3 Tesla
  • Spatial gradient field of 2500 Gauss/cm or less
  • Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for up to 15 minutes of scanning for each sequence

The XIENCE Alpine stent should not migrate in this MRI environment. MRI at 1.5 or 3 Tesla may be performed immediately post-implantation.

At the tested parameters noted above, the XIENCE Alpine stent produced a nonclinical maximum local temperature increase of 3.3°C. This does not take into consideration the cooling effects of blood flow.

An image artifact can be present, and MRI image quality may be compromised if the area of interest is at or near the stent position. Therefore, it may be necessary to optimize the MRI parameters to account for the presence of the XIENCE stent.

Refer to the IFU for Additional Information.

What are the sizes of XIENCE Alpine?

The XIENCE Alpine stent is available at lengths (mm) of:
8, 12, 15, 18, 23, 28, 33, 38

It is available in diameters (mm) of:
2.25, 2.5, 2.75, 3.0, 3.25, 3.5, 4.0

View ordering information here.

What are the unique properties of the XIENCE polymer?

The specific fluoropolymer used—based on years of research—plays a critical role in XIENCE's superior outcomes. Abbott successfully identified a polymer that offers both mechanical integrity and scientific evidence of biocompatibility. Extensive research showed that polymers with a fluorinated surface were associated with “protective” attributes, such as the ability to tightly bind albumin to create a “protective cloak” around the stent.1-4 This results in the following characteristics, collectively known as fluoropassivation:

  • Thromboresistance, referring to the preferential adsorption and retention of good protein (e.g., albumin) vs thrombogenic proteins (e.g., fibrinogen)—leading to less platelet adhesion and activation.1-4
  • Minimal inflammatory response,1 since the preferential adsorption of albumin minimizes platelet adhesion, leukocyte activation and leukocyte recruitment.
  • Functional healing, since preferential albumin adsorption elicits a cellular response conducive to healing, with rapid formation of functional endothelium and minimal chronic inflammation.1,5-6

Thus the XIENCE fluoropolymer was created to ensure long-term protection to the vessel and ultimately to the patient.

What is the dual antiplatelet therapy (DAPT) duration with XIENCE?

With more than 16,000 XIENCE patients involved in DAPT studies, Abbott has received a 1-month DAPT CE Label update. A study recently examined stent thrombosis (ST) and DAPT use through 2 years in a large pooled sample of patients from the XIENCE family of clinical studies.7 The study revealed that discontinuing DAPT:

  • Before 1 month was strongly associated with ST
  • After 3 months appeared safe

In addition, the STOPDAPT trial8 revealed 0% definite or probable ST with XIENCE when DAPT was discontinued at 3 months. Learn more about DAPT.

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.

Sign up

* The effects of MRI on overlapped stents greater than 71 mm in length, or involving stents with fractured struts, are unknown.

† The request for a sample must come from the patient’s allergist or dermatologist, who will conduct the specific testing. The material provided—which will be non-sterile—will be a stent manufactured from the same type of stock 316L stainless steel or L-605 cobalt chromium alloy material, but may not be an identical stent pattern to the patient's implant.  

  1. Paton DM, et al. U.S. Patent 5,356,668.
  2. Garfinkle AM, et al. Trans Am Soc Artif Intern Organs. 1984;30:432-439.
  3. Fluorinated surfaces have been used for cardiovascular implants to benefit from thromboresistance and long-term biocompatibility.
  4. Ao PY, et al. Eur J Vasc Endovasc Surg. 2000;20:241-249.
  5. Lilenfeld R, et al. U.S. Patent 4,564,013.
  6. Chinn JA, et al. J Biomed Mater Res. 1998;39:130-140.
  7. Généreux P, et al. Circ Cardiovasc Interv. 2015;8:e001362. doi:10.1161/CIRCINTERVENTIONS.114.001362.
  8. Natsuaki M, et al. STOPDAPT Trial. Cardiovasc Interv Ther. 2016;31:196–209.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Disclaimer is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit the International section of this website?